• Skip to primary navigation
  • Skip to main content
Finnish Society of Gene and Cell Therapy

FSGCT

Finnish Society of Gene and Cell Therapy

  • Home
  • About Us
    • About Us
    • Board
    • President’s message 
    • GDPR statement
  • Events and news
    • News
    • Events
    • Travel grants
  • Useful information
    • Gene and cell therapy societies
    • Further reading
  • Sponsors
  • Contact Us
    • Inform us about your event
  • Suomi
  • Show Search
Hide Search

Finnish gene therapy for bladder cancer approved by FDA

January 5, 2023

Ferring Pharmaceuticals has announced that the novel gene therapy for bladder cancer developed by its sister company FinVector Oy has been approved by FDA. FinVector Oy has developed gene medicines in Kuopio for 30 years, and the development of gene therapy for bladder cancer was also already started in the 1990s.

Adstiladrin® (nadofaragene firadenovec-vncg) contains modified adenoviruses carrying a human gene that stimulates immune responses (IFNα). The medicine works by entering and killing cancer cells, which then further stimulates the patient’s own immune system to kill more cancer cells.

Read more on the FinVector website.

News

© Copyright 2020 Finnish Society of Gene and Cell Therapy · All Rights Reserved


Tietosuojakäytäntö · Privacy policy